ASAsim Shaikh

Asim Shaikh

*This is an algorithmically generated author record based on publicly available information.

Asim Shaikh has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Obesity-based modulation of positron emission tomography myocardial blood flow reserve

    by Asim Shaikh, Maria Alwan, Ahmed Sayed, Ahmad El-Yaman, Mouaz H. Al-Mallah, Mahmoud Al Rifai

  • Cardiac nuclear imaging workforce: Trends from Medicare Part B (2013–2022)

    by Maria Alwan, Ahmad El Yaman, Ahmed Sayed, Asim Shaikh, Lawrence M. Phillips, Mahmoud Al Rifai, Mouaz H. Al-Mallah


  • Geographical distribution and accessibility to cardiac CT readers in the United States: A snapshot from the 2022 medicare analysis

    by Ahmad El Yaman, Alaaeddine El Ghazawi, Ahmed Sayed, Maria Alwan, Asim Shaikh, Mahmoud Al Rifai, Leslee J. Shaw, Maros Ferencik, Mouaz H. Al-Mallah


  • Cardiac positron emission tomography/Computed tomography (PET/CT) in current cardiology guidelines

    by Maria Alwan, Ahmad El Yaman, Ahmed Sayed, Asim Shaikh, Mahmoud Al Rifai, Mouaz H. Al-Mallah


  • Open Access

    The Pulse of AI: Implementation of Artificial Intelligence in Healthcare and its Potential Hazards

    by Syeda Farheen Zaidi, Asim Shaikh, Salim Surani

    In this editorial, we explore the existing utilization of artificial intelligence (AI) within the healthcare industry, examining both its scope and potential harms if implemented and relied upon on a broader scale. Collaboration among corporations, government bodies, policymakers, and medical experts is essential to address potential concerns, ensuring smooth AI integration into healthcare systems.


  • Open Access

    Role of soluble urokinase type plasminogen activator receptor (suPAR) in predicting mortality, readmission, length of stay and discharge in emergency patients: A systematic review and meta analysis

    by Syeda Tayyaba Mbbs Rehan, Hassan Ul Mbbs Hussain, Eman Mbbs Ali, Kanwal Ashok Mbbs Kumar, Shehroze Mbbs Tabassum, Muhammad Mbbs Hasanain, Asim Mbbs Shaikh, Gibran Ali, Zohaib Md Yousaf, Muhammad Sohaib Mbbs Asghar

    Background: Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker that is used to predict mortality, readmission, early discharge, and LOS, thus, serves as a useful tool for ED physicians. Our study aims to analyze the efficacy of suPAR in predicting these prognostic markers in ED. Methods: We performed a comprehensive search on 6 databases from the inception to 30th November 2022, to select the following eligibility criteria; a) observation or triage trial studies investigating the role of suPAR levels in predicting: 30 day and 90-day mortality, 30-day readmission, early discharge (within 24hr), and LOS in patients coming to AMU. Results: A total of 13 studies were included, with a population size of 35,178, of which 52.9% were female with a mean age of 62.93 years. Increased risk of 30-day mortality (RR = 10.52; 95% CI = 4.82–22.95; I2 = 38%; P < .00001), and risk of 90-day mortality (RR = 5.76; 95% CI = 3.35–9.91; I2 = 36%; P < .00001) was observed in high suPAR patients. However, a slightly increased risk was observed for 30-day readmission (RR = 1.50; 95% CI = 1.16–1.94; I2 = 54%; P = .002). More people were discharged within 24hr in the low suPAR level group compared to high suPAR group (RR = 0.46; 95% CI = 0.40–0.53; I2 = 41%; P < .00001). LOS was thrice as long in high suPAR level patients than in patients with low suPAR (WMD = 3.20; 95% CI = 1.84–4.56; I2 = 99%; P < .00001). Conclusion: suPAR is proven to be a significant marker in predicting 30-day and 90-day mortality in ED patients.


  • Open Access

    Caregiver’s perceptions of COVID-19 vaccination, and intention to vaccinate their children against the disease: a questionnaire based qualitative study

    by Farah Mbbs Yasmin, Kanchan Mbbs Kumari, Kanza Mbbs Saleem, Iqra Mbbs Lareeb, Asim Mbbs Shaikh, Rija Mbbs Ashfaq, Bilal Mbbs Ahmed, Nermeen Mbbs Bashar, Hala Mbbs Najeeb, Muhammad Sohaib Mbbs Asghar

    Coronavirus disease 2019 (COVID-19) vaccine side effects have an important role in the hesitancy of the general population toward vaccine administration. Another reason for vaccine hesitancy might be that healthcare professionals may not address their concerns regarding vaccines appropriately. Regardless, hesitancy in the form of delay, refusal, or acceptance with doubts about its usefulness can limit the downward trajectory of the COVID-19 pandemic. Therefore, the authors conducted a national cross-sectional study (n=306) to assess causes and concerns for vaccine hesitancy in caregivers in Pakistan toward getting their children vaccinated. The questions identified caregivers by socioeconomic demographics, perceived COVID-19 pandemic severity, and concerns toward the COVID-19 vaccine. The majority of the participants were 45–59 years of age (42.8%) with a mean age of 36.11 years (SD: 7.81). A total of 80% of these participants were willing to vaccinate their child with any COVID-19 vaccine. Present comorbidities had a frequency of 28.4% (n=87/306) and only 26.9% (n=66/245) participants were willing to vaccinate their child. Participants with high social standing were 15.4% (n=47/306) with the majority of them being willing to vaccinate their children (45/47). Socioeconomic status (OR:2.911 [0.999–8.483]), and the child’s vaccinations being up to date (OR:1.904 [1.078–3.365]) were found to be independent factors for caregivers to be willing to vaccinate their child. Around 62% (n=191/306) were not willing to vaccinate due to the concern for side effects, 67.6% (n=207/306) were not willing because they did not have ample information available, and 51% (n=156/306) were not willing as they were concerned about vaccine effectiveness. Further studies on vaccine safety in the pediatric population are required to improve caregivers’ perceptions.

  • The COVID-19 Pandemic and Coronary Heart Disease: the Next Surge

    by Asim Shaikh, Sarim Dawar Khan, Farhala Baloch, Salim S. Virani, Zainab Samad

    Purpose of Review In this narrative review, we highlight different ways in which the COVID-19 pandemic has impacted coronary heart disease (CHD) burden and how a surge in morbidity and mortality may be expected in the near future. We also discuss potential solutions, and the direction subsequent research and corrective actions should take. Recent Findings COVID-19 has been implicated in the development and worsening of CHD via acute and chronic mechanisms in the form of plaque rupture, destabilization, and sustenance of a chronic inflammatory state leading to long COVID syndrome and increased rates of myocardial infarction. However, indirectly the pandemic is likely to further escalate the CHD burden through poor health behaviors such as tobacco consumption, reduced physical activity, economic devastation and its associated sequelae, and regular cardiac care interruptions and delays. Summary COVID-19 has increased the total CHD burden and will require extensive resource allocation and multifaceted strategies to curb future rise.


  • Open Access

    Vasoplegia: A Review

    by Iqbal Ratnani, Rohan Kumar Ochani, Asim Shaikh, Hafsa Nazir Jatoi

    Vasoplegia is a condition characterized by persistent low systemic vascular resistance despite a normal or high cardiac index, resulting in profound and uncontrolled vasodilation. Vasoplegia may occur due to various conditions, including cardiac failure, sepsis, and post-cardiac surgery. In the cardiac cohort, multiple risk factors for vasoplegia have been identified. Several factors contribute to the pathophysiology of this condition, and various mechanisms have been proposed, including nitric oxide, adenosine, prostanoids, endothelins, the renin-angiotensin-aldosterone system, and hydrogen sulfide. Early identification and prompt management of vasoplegia is crucial to prevent development of shock. This review expands upon the different vasopressors used in management of vasoplegia, including catecholamines such as norepinephrine, dopamine, epinephrine, phenylephrine, and other agents including vasopressin, methylene blue, angiotensin II, hydroxocobalamin, vitamin C, thiamine, and corticosteroids (ie, hydrocortisone). It also emphasizes the importance of conducting further research and making advancements in treatment regimens for vasoplegia.


  • Open Access

    Comprehensive overview of human monkeypox: epidemiology, clinical features, pathogenesis, diagnosis and prevention

    by Eman Mbbs Ali, Ayesha Mbbs Sheikh, Rabia Mbbs Owais, Asim Mbbs Shaikh, Unaiza Mbbs Naeem

    Monkeypox (MPX) is a zoonotic disease caused by the monkeypox virus (MPXV), belonging to the orthopoxvirus genus with a presentation resembling smallpox making it historically challenging to distinguish the disease from smallpox clinically. Since a British citizen brought MPX into the country on 6 May 2022, there have been concerns about the re-emergence of the human MPXV. Since then, the WHO has reported 92 confirmed cases and 28 suspected cases in 13 nations where MPXV was not endemic. WHO declared MPX a ‘public health emergency of international concern’ on 23 July 2022. MPXV can spread either through human-human contact or animal-human contact. Respiratory droplets, direct contact with bodily fluids, contaminated patient surroundings or objects, and skin sores from an infected person have all been linked to the disease’s transmission from one person to another. Fever, headache, lethargy, asthenia, enlargement of the lymph nodes, weariness, back pain, and myalgia are some of the symptoms that last from 2 to 5 weeks. It can be diagnosed using a range of diagnostic methods, including electron microscopy, Immunoglobulin M, enzyme-linked immunosorbent assay, polymerase chain reactions, histological analysis, immunofluorescent antibody testing, virus isolation, etc. Smallpox immunization before infection may lessen clinical symptoms and is around 85% effective in protecting from the MPXV.